SGEN stock remains tied to Seagen acquisition context.

Seagen, Inc. is identified by ISIN US8166361055, and SGEN stock remains best understood through the company record around its oncology-focused business and the Pfizer acquisition context.

Company record

Seagen reported full-year 2022 product revenue of $2.02 billion, up 22% from $1.65 billion in 2021, according to its annual report. The same filing showed net loss narrowed to $255 million from $512 million a year earlier, while cash, cash equivalents and investments stood at $1.97 billion at year-end 2022.

Acquisition context

Pfizer completed its acquisition of Seagen in 2023, a deal that removed the shares from the usual live-market setup and left the security tied to the corporate-action record rather than a current operating quote. That context matters for investors who track the legacy security, because the underlying business data now sits in the archived reporting trail instead of an active standalone equity story.

Revenue still leads

Seagen's 2022 revenue of $2.02 billion versus $1.65 billion in 2021 gives a quantified comparison that still defines the scale of the franchise. The 22% rise also shows why the oncology portfolio drew strategic interest before the transaction closed.

Product mix

ADCETRIS remained one of Seagen's core marketed products, alongside TUKYSA, PADCEV and TIVDAK, and the annual report framed the company around those four commercial oncology brands. That product mix explains the revenue base that reached $2.02 billion in 2022.

Legacy quote frame

The stock no longer trades as a normal standalone New York listing after the takeover, so the most relevant market reference is the archived corporate value embedded in the acquisition history rather than a fresh intraday price. Seagen's legacy profile therefore matters more as a recorded deal and filing story than as a live quote story.

ADCETRIS remains central

ADCETRIS was Seagen's best-known revenue driver, and the annual report placed it at the center of the company's commercial portfolio. Together with PADCEV, TUKYSA and TIVDAK, it explains why the 2022 revenue base reached $2.02 billion.

Legacy security status

The legacy SGEN line is now best read as a historical reference point for Seagen's 2022 operating scale and the subsequent Pfizer takeover. For market history, the key dated markers are the $2.02 billion revenue figure, the $255 million net loss and the $1.97 billion cash-and-investment balance at 31 December 2022.